New Immuno-Chemo Combo for Advanced Cervical Cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy (with or without an anti-VEGF drug) followed by standard chemoradiation for women with advanced cervical cancer that hasn't spread beyond the pelvis. It aims to see if this approach can shrink tumors more effectively than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cervical cancer confirmed by biopsy (squamous cell, adenocarcinoma, or adenosquamous).
- Your cancer must be at a high-risk local stage (IB3–IIIC with large tumor or lymph node issues) or stage IVA that hasn't spread beyond the pelvis.
- You cannot have had any prior cancer treatment (radiation, chemo, immunotherapy, or targeted therapy) for your cervical cancer.
- You must have your uterus intact (no hysterectomy) because brachytherapy is part of the treatment.
- Your cancer must not have spread to distant organs (like lungs, liver, or lymph nodes outside the pelvis).
- You must be willing to provide tumor tissue, blood, urine, and other samples during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
This trial tests adding a new immunotherapy drug (cadonilimab) to standard chemotherapy before surgery for locally advanced cervical cancer. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This trial tests a new combination of chemotherapy and immunotherapy before standard chemoradiation for locally advanced cervical cancer. The goal is to see if adding immunotherapy first helps shrink the tumor and improve treatment outcomes.
Hear when a new Cervical Cancer Stage IVA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.